Respiratory effects of live influenza virus vaccine: healthy older subjects and patients with chronic respiratory disease.
Twenty-one healthy, middle-aged volunteers and 8 patients with chronic lung disease were given live, attenuated influenza virus vaccine by nasal spray. Forced vital capacity, 1-sec forced expiratory volume, ratio of 1-sec forced expiratory volume to forced vital capacity, residual volume, ratio of airway conductance to lung volume, maximal expiratory flows after exhalation of 50 and of 75 per cent of the forced vital capacity, closing volume, slope of Phase III, volume of isoflow, single-breath diffusing capacity for CO, and arterial blood gases were measured before and 3, 7, 10, and 21 days after exposure. Vaccination was well tolerated by the healthy volunteers without change in pulmonary function. In contrast, the patients tended to develop increased respiratory symptoms and had a slight decrease in mean forced expiratory volume in 1 sec 3 weeks after vaccination.
D000281:Administration, Intranasal; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007252:Influenza Vaccines / Q000009:adverse effects*; D007321:Inspiratory Reserve Volume; D008171:Lung Diseases / Q000150:complications* / Q000503:physiopathology; D008176:Lung Volume Measurements; D008297:Male; D008875:Middle Aged; D012115:Residual Volume; D012119:Respiration; D014109:Total Lung Capacity; D014613:Vaccines, Attenuated / Q000009:adverse effects
D007252:Influenza Vaccines; D014613:Vaccines, Attenuated